Profund Advisors LLC Has $1.09 Million Stock Holdings in Syneos Health Inc (NASDAQ:SYNH)

Profund Advisors LLC lessened its holdings in shares of Syneos Health Inc (NASDAQ:SYNH) by 8.7% in the 2nd quarter, Holdings Channel.com reports. The firm owned 21,347 shares of the company’s stock after selling 2,045 shares during the quarter. Profund Advisors LLC’s holdings in Syneos Health were worth $1,091,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. AlphaOne Investment Services LLC lifted its position in shares of Syneos Health by 544.5% during the 2nd quarter. AlphaOne Investment Services LLC now owns 10,248 shares of the company’s stock worth $523,000 after purchasing an additional 8,658 shares during the last quarter. Scotia Capital Inc. acquired a new position in shares of Syneos Health during the 2nd quarter worth about $1,542,000. Parametric Portfolio Associates LLC lifted its position in shares of Syneos Health by 18.8% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 301,841 shares of the company’s stock worth $15,421,000 after purchasing an additional 47,822 shares during the last quarter. Meadow Creek Investment Management LLC lifted its position in shares of Syneos Health by 21.1% during the 2nd quarter. Meadow Creek Investment Management LLC now owns 12,682 shares of the company’s stock worth $648,000 after purchasing an additional 2,210 shares during the last quarter. Finally, Glen Harbor Capital Management LLC lifted its position in shares of Syneos Health by 21.1% during the 2nd quarter. Glen Harbor Capital Management LLC now owns 8,206 shares of the company’s stock worth $419,000 after purchasing an additional 1,430 shares during the last quarter.

SYNH traded up $0.75 on Monday, hitting $55.42. 13,926 shares of the stock traded hands, compared to its average volume of 389,826. Syneos Health Inc has a 52 week low of $36.26 and a 52 week high of $56.34. The company has a current ratio of 0.89, a quick ratio of 0.89 and a debt-to-equity ratio of 0.99. The firm has a market capitalization of $5.62 billion, a PE ratio of 21.08, a P/E/G ratio of 1.90 and a beta of 1.51. The business has a fifty day moving average price of $51.16 and a two-hundred day moving average price of $48.13.

Syneos Health (NASDAQ:SYNH) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $0.61 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.02. Syneos Health had a return on equity of 9.82% and a net margin of 0.36%. The firm had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.15 billion. During the same period in the previous year, the company posted $0.62 earnings per share. The company’s quarterly revenue was up 8.8% compared to the same quarter last year. On average, equities research analysts forecast that Syneos Health Inc will post 2.73 EPS for the current fiscal year.

SYNH has been the subject of several research analyst reports. Zacks Investment Research cut Syneos Health from a “buy” rating to a “hold” rating and set a $55.00 price objective for the company. in a research report on Tuesday, September 10th. UBS Group boosted their price target on Syneos Health from $53.50 to $57.00 and gave the company a “neutral” rating in a research note on Thursday, August 29th. SunTrust Banks boosted their price target on Syneos Health to $68.00 and gave the company a “buy” rating in a research note on Wednesday, August 7th. KeyCorp boosted their price target on Syneos Health from $63.00 to $65.00 and gave the company an “overweight” rating in a research note on Tuesday, September 3rd. Finally, Credit Suisse Group boosted their price target on Syneos Health from $56.00 to $58.00 and gave the company an “outperform” rating in a research note on Friday, August 23rd. Five analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Syneos Health presently has an average rating of “Buy” and an average price target of $58.63.

Syneos Health Company Profile

Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.

Read More: Why do corrections happen?

Want to see what other hedge funds are holding SYNH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Syneos Health Inc (NASDAQ:SYNH).

Institutional Ownership by Quarter for Syneos Health (NASDAQ:SYNH)

Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.